Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Cancer Discov. 2018 May 17;8(7):822–835. doi: 10.1158/2159-8290.CD-18-0099

Figure 1. STK11/LKB1 co-mutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC.

Figure 1

A. Objective response rate (RECISTv1.1) to PD-1 axis blockade in the KL, KP and K-only subgroups in the overall SU2C population (N=173 response-evaluable patients) and in each of the three independent cohorts (MDACC, MSKCC, DFCI/MGH). A two-tailed Fisher’s exact test (computed from a 2×3 contingency table) was used to assess the significance of the association between group membership and best overall response (PR/CR vs SD/PD). B. Objective response rate to nivolumab in the KL, KP and K-only subgroups in the CheckMate-057 international randomized phase III clinical trial (N=24). A two-tailed Fisher’s exact test (computed from a 2×3 contingency table) was used to assess the significance of the association between group membership and best overall response (PR/CR vs SD/PD). C. Waterfall plots illustrating individual patient-level maximal % change in tumor burden from baseline in response to PD-1/PD-L1 inhibition in the SU2C cohort. Only data from response-evaluable patients with measurable disease are graphed.